Travel and Tropical Medicine

A returning traveler with cerebral and renal involvement from severe P. falciparum malaria, at a hospital with no IV artesunate on site. The disagreement isn't about whether he needs the drug — it's about whether oral bridging therapy can be trusted in a patient whose gut perfusion may already be compromised, or whether everything should ride on transfer instead.

A field geologist with CKD stage 4 needs malaria chemoprophylaxis for a six-week remote assignment in a chloroquine-resistant region. Atovaquone-proguanil, the usual first reach, is contraindicated by its own label at her renal function — the debate is which of the two labeled alternatives actually fits her circumstances, or whether the first choice deserves a second look after all.

A nurse-midwife returning from four months in rural Rwanda has an uncomplicated P. falciparum infection, started on standard first-line artemether-lumefantrine — and a Day-3 smear that still shows scant parasites, in a region with confirmed kelch13 partial-resistance mutations. The debate is whether that finding means anything for her specifically, or whether it's exactly the kind of ambiguous signal the surveillance data warns against over-reading.

A newly retired cyclist wants a standby antibiotic prescription before a month alone on rural roads in Vietnam and Cambodia. The disagreement isn't about whether traveler's diarrhea is a real risk for him — it's about whether handing him an antibiotic at all is the right answer, given how the resistance and colonization data have shifted.

A software engineer back from three weeks in Karachi has a classic stepwise fever and suspected typhoid, in a region where the circulating strain is resistant to fluoroquinolones and third-generation cephalosporins together. The debate isn't just which drug to start — it's whether he can safely be treated as an outpatient at all before culture results are back.

A pregnant woman develops fever, an eschar, and a rash ten days after a South African safari — a textbook presentation of African tick bite fever. The disagreement isn't about the diagnosis — it's about whether the tetracycline caution generations of clinicians absorbed from a rickettsiosis that kills should govern one that, on the record, never has.

An ER nurse who competed in a multi-day Costa Rica adventure race develops classic leptospirosis, started on oral doxycycline — and by Day 2 her bilirubin and creatinine have both nudged upward. The debate is whether that's the early signature of Weil's disease demanding IV penicillin, or a mild trend the actual antibiotic evidence doesn't clearly say is worth escalating for.

A college student develops classic Katayama syndrome five weeks after swimming in Lake Malawi — fever, urticarial rash, hepatosplenomegaly, marked eosinophilia. Praziquantel is the right drug eventually, but it doesn't reliably kill the immature schistosomula still migrating at this stage. The question is whether to treat now anyway, or wait for a single dose more likely to work.

A Vietnam veteran's routine annual physical turns up incidental eosinophilia and, on closer questioning, a fifty-year-old exposure history and a rash he's been told for decades is probably an allergy. The debate is whether to treat presumptively for Strongyloides now, or wait on a serology test whose sensitivity, while good, isn't perfect.

A blood donation deferral letter is how D.M. learned he has Chagas disease, fifteen years after leaving rural Bolivia. His echocardiogram is normal — chronic indeterminate phase, no cardiomyopathy. The one major trial of antitrypanosomal treatment found no cardiac benefit, but it studied patients who already had heart disease. Whether that result applies to him at all is the actual question.

A wildlife photographer returns from three months across Botswana, Zambia, and Uganda with no symptoms at all, just an eosinophil count flagged on routine post-travel screening and a trip full of genuinely distinct parasitic exposures. Nothing points clearly toward one diagnosis — the debate is whether to treat broadly now or test first and treat what's actually found.

A returning traveler recovering from an acute P. vivax attack now needs radical cure therapy to clear the dormant liver hypnozoites that cause relapse. Tafenoquine offers a single dose against primaquine's real-world adherence problem over fourteen days — but it demands a stricter, slower G6PD test than primaquine ever has.